FR23C1008I2 - TRANSTHYRETIN (TTR) RNAI COMPOSITIONS AND METHODS OF USING THEM FOR THE TREATMENT OR PREVENTION OF TTR-ASSOCIATED DISEASES - Google Patents

TRANSTHYRETIN (TTR) RNAI COMPOSITIONS AND METHODS OF USING THEM FOR THE TREATMENT OR PREVENTION OF TTR-ASSOCIATED DISEASES

Info

Publication number
FR23C1008I2
FR23C1008I2 FR23C1008C FR23C1008C FR23C1008I2 FR 23C1008 I2 FR23C1008 I2 FR 23C1008I2 FR 23C1008 C FR23C1008 C FR 23C1008C FR 23C1008 C FR23C1008 C FR 23C1008C FR 23C1008 I2 FR23C1008 I2 FR 23C1008I2
Authority
FR
France
Prior art keywords
ttr
transthyretin
prevention
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR23C1008C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alnylam Pharmaceuticals Inc
Original Assignee
Alnylam Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alnylam Pharmaceuticals Inc filed Critical Alnylam Pharmaceuticals Inc
Publication of FR23C1008I1 publication Critical patent/FR23C1008I1/en
Application granted granted Critical
Publication of FR23C1008I2 publication Critical patent/FR23C1008I2/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533—Halogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
FR23C1008C 2015-07-31 2023-02-08 TRANSTHYRETIN (TTR) RNAI COMPOSITIONS AND METHODS OF USING THEM FOR THE TREATMENT OR PREVENTION OF TTR-ASSOCIATED DISEASES Active FR23C1008I2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562199563P 2015-07-31 2015-07-31
US201662287518P 2016-01-27 2016-01-27
PCT/US2016/044359 WO2017023660A1 (en) 2015-07-31 2016-07-28 TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES

Publications (2)

Publication Number Publication Date
FR23C1008I1 FR23C1008I1 (en) 2023-03-24
FR23C1008I2 true FR23C1008I2 (en) 2024-04-05

Family

ID=56682264

Family Applications (1)

Application Number Title Priority Date Filing Date
FR23C1008C Active FR23C1008I2 (en) 2015-07-31 2023-02-08 TRANSTHYRETIN (TTR) RNAI COMPOSITIONS AND METHODS OF USING THEM FOR THE TREATMENT OR PREVENTION OF TTR-ASSOCIATED DISEASES

Country Status (33)

Country Link
US (4) US10208307B2 (en)
EP (1) EP3329002B1 (en)
JP (3) JP6896703B2 (en)
KR (2) KR20240074895A (en)
CN (2) CN108138182B (en)
BR (1) BR112018000542B1 (en)
CA (1) CA2994285A1 (en)
CL (1) CL2018000198A1 (en)
CY (1) CY1124545T1 (en)
DK (1) DK3329002T3 (en)
EA (1) EA201890394A1 (en)
ES (1) ES2842300T3 (en)
FI (1) FIC20230006I1 (en)
FR (1) FR23C1008I2 (en)
HK (2) HK1256494A1 (en)
HR (1) HRP20202082T1 (en)
HU (2) HUE051998T2 (en)
IL (3) IL296476B1 (en)
LT (2) LT3329002T (en)
MA (1) MA43335B1 (en)
MX (2) MX2018000981A (en)
MY (1) MY195720A (en)
NL (1) NL301216I2 (en)
NO (1) NO2023007I1 (en)
PL (1) PL3329002T3 (en)
PT (1) PT3329002T (en)
RS (1) RS61297B1 (en)
SG (1) SG10201912341SA (en)
SI (1) SI3329002T1 (en)
TW (3) TWI727963B (en)
UA (1) UA126276C2 (en)
WO (1) WO2017023660A1 (en)
ZA (2) ZA201800571B (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2616051T3 (en) 2008-12-02 2017-06-09 Wave Life Sciences Japan, Inc. Method for the synthesis of modified nucleic acids in the phosphorus atom
WO2011005761A1 (en) 2009-07-06 2011-01-13 Ontorii, Inc Novel nucleic acid prodrugs and methods use thereof
MX343559B (en) 2010-04-29 2016-11-10 Ionis Pharmaceuticals Inc Modulation of transthyretin expression.
JP5868324B2 (en) 2010-09-24 2016-02-24 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ Asymmetric auxiliary group
WO2013012758A1 (en) 2011-07-19 2013-01-24 Ontorii, Inc. Methods for the synthesis of functionalized nucleic acids
KR102263352B1 (en) 2011-11-18 2021-06-11 알닐람 파마슈티칼스 인코포레이티드 RNAi AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASES
EA201490993A1 (en) 2011-11-18 2014-09-30 Элнилэм Фармасьютикалз, Инк. MODIFIED MEANS OF RNA
WO2014010250A1 (en) 2012-07-13 2014-01-16 Chiralgen, Ltd. Asymmetric auxiliary group
SG11201500232UA (en) 2012-07-13 2015-04-29 Wave Life Sciences Pte Ltd Chiral control
JPWO2015108048A1 (en) 2014-01-15 2017-03-23 株式会社新日本科学 Chiral nucleic acid adjuvant and antitumor agent having antitumor activity
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
KR20230152178A (en) 2014-01-16 2023-11-02 웨이브 라이프 사이언시스 리미티드 Chiral design
MX2018000981A (en) 2015-07-31 2018-06-11 Alnylam Pharmaceuticals Inc TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES.
JOP20210043A1 (en) * 2015-10-01 2017-06-16 Arrowhead Pharmaceuticals Inc Compositions and Methods for Inhibiting Gene Expression of LPA
US20190350962A1 (en) * 2016-12-16 2019-11-21 Alnylam Pharmaceuticals, Inc. METHODS FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES USING TRANSTHYRETIN (TTR) iRNA COMPOSITIONS
KR20200089656A (en) 2017-09-19 2020-07-27 알닐람 파마슈티칼스 인코포레이티드 Compositions and methods for treating transthyretin (TTR) mediated amyloidosis
AU2018374219C1 (en) * 2017-12-01 2023-05-11 Suzhou Ribo Life Science Co., Ltd. Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method therefor and use thereof
EP3856907A1 (en) 2018-09-28 2021-08-04 Alnylam Pharmaceuticals, Inc. Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
WO2021041884A1 (en) 2019-08-30 2021-03-04 Alnylam Pharmaceuticals, Inc. Neurofilament light chain (nfl) as a biomarker for transthyretin amyloidosis polyneuropathy
JP2023516748A (en) 2020-03-06 2023-04-20 アルナイラム ファーマシューティカルズ， インコーポレイテッド Compositions and methods for inhibiting expression of transthyretin (TTR)
WO2022094152A1 (en) * 2020-10-28 2022-05-05 Neotope Neuroscience Limited Anti-transthyretin antibodies and methods of use thereof
WO2022260939A2 (en) 2021-06-08 2022-12-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for treating or preventing stargardt's disease and/or retinal binding protein 4 (rbp4)-associated disorders
EP4381067A1 (en) 2021-08-03 2024-06-12 Alnylam Pharmaceuticals, Inc. Transthyretin (ttr) irna compositions and methods of use thereof
WO2024130142A2 (en) * 2022-12-16 2024-06-20 Amgen Inc. Rnai constructs for inhibiting ttr expression and methods of use thereof

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030027216A1 (en) 2001-07-02 2003-02-06 Kiernan Urban A. Analysis of proteins from biological fluids using mass spectrometric immunoassay
AU2001247951A1 (en) 2000-02-07 2001-08-14 Roche Diagnostics Corporation Novel cationic amphiphiles
WO2002081628A2 (en) 2001-04-05 2002-10-17 Ribozyme Pharmaceuticals, Incorporated Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
US20030072794A1 (en) 2000-06-09 2003-04-17 Teni Boulikas Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
SI1407044T2 (en) 2000-12-01 2018-03-30 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Rna interference mediating small rna molecules
US20020160394A1 (en) 2001-01-24 2002-10-31 Bayer Corporation Regulation of transthyretin to treat obesity
US20030170891A1 (en) 2001-06-06 2003-09-11 Mcswiggen James A. RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA)
WO2003001182A2 (en) 2001-06-21 2003-01-03 The Cleveland Clinic Foundation Homocysteinylated transthyretin
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
DK3222724T3 (en) 2002-08-05 2018-12-03 Silence Therapeutics Gmbh ADDITIONALLY UNKNOWN FORMS OF INTERFERRING RNA MOLECULES
US7923547B2 (en) 2002-09-05 2011-04-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
CA2502413A1 (en) 2002-11-01 2004-05-21 The Regents Of The University Of Colorado, A Body Corporate Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
ATE517992T1 (en) 2002-11-14 2011-08-15 Dharmacon Inc FUNCTIONAL AND HYPERFUNCTIONAL SIRNA
US8110674B2 (en) 2003-03-07 2012-02-07 Alnylam Pharmaceuticals, Inc. Therapeutic compositions
CA2488224A1 (en) 2003-04-03 2004-10-21 Alnylam Pharmaceuticals, Inc. Irna conjugates
CA2532228C (en) 2003-07-16 2017-02-14 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
US20050244869A1 (en) 2004-04-05 2005-11-03 Brown-Driver Vickie L Modulation of transthyretin expression
AU2005252663B2 (en) 2004-06-03 2011-07-07 Isis Pharmaceuticals, Inc. Double strand compositions comprising differentially modified strands for use in gene modulation
WO2005120152A2 (en) 2004-06-07 2005-12-22 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use
AU2005252273B2 (en) 2004-06-07 2011-04-28 Arbutus Biopharma Corporation Lipid encapsulated interfering RNA
US7838561B2 (en) 2004-06-14 2010-11-23 Wisconsin Alumni Research Foundation Method for preventing or treating cardiac hypertrophy
CA2584845C (en) 2004-12-08 2009-02-17 Sirion Therapeutics, Inc. Methods, assays and compositions for treating retinol-related diseases
JP5042863B2 (en) 2005-02-14 2012-10-03 サーナ・セラピューティクス・インコーポレイテッド Lipid nanoparticle-based compositions and methods for delivering biologically active molecules
WO2006105361A2 (en) 2005-03-31 2006-10-05 Calando Pharmaceuticals, Inc. Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
US7915230B2 (en) 2005-05-17 2011-03-29 Molecular Transfer, Inc. Reagents for transfection of eukaryotic cells
AU2006274413B2 (en) 2005-07-27 2013-01-10 Arbutus Biopharma Corporation Systems and methods for manufacturing liposomes
EP1948674A4 (en) 2005-11-02 2009-02-04 Protiva Biotherapeutics Inc Modified sirna molecules and uses thereof
CA2647728C (en) 2006-03-31 2014-12-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of eg5 gene
US8598333B2 (en) 2006-05-26 2013-12-03 Alnylam Pharmaceuticals, Inc. SiRNA silencing of genes expressed in cancer
MX363224B (en) 2006-10-03 2019-03-15 Alnylam Pharmaceuticals Inc Lipid containing formulations.
GB0704764D0 (en) 2007-03-12 2007-04-18 Electrophoretics Ltd Isobarically labelled reagents and methods of their use
WO2009002944A1 (en) 2007-06-22 2008-12-31 Isis Pharmaceuticals, Inc. Double strand compositions comprising differentially modified strands for use in gene modulation
AU2008333811B2 (en) 2007-12-04 2014-05-01 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
AU2008342535B2 (en) 2007-12-27 2015-02-05 Arbutus Biopharma Corporation Silencing of polo-like kinase expression using interfering RNA
EP2224912B1 (en) 2008-01-02 2016-05-11 TEKMIRA Pharmaceuticals Corporation Improved compositions and methods for the delivery of nucleic acids
AU2009241591A1 (en) 2008-01-31 2009-11-05 Alnylam Pharmaceuticals, Inc. Optimized methods for delivery of DSRNA targeting the PCSK9 gene
US20100323381A1 (en) 2008-02-08 2010-12-23 Bergen Iii Harold R Classifying amyloidosis
PT2279254T (en) 2008-04-15 2017-09-04 Protiva Biotherapeutics Inc Novel lipid formulations for nucleic acid delivery
TWI455944B (en) 2008-07-01 2014-10-11 Daiichi Sankyo Co Ltd Double-stranded polynucleotides
EP2323667A4 (en) 2008-08-07 2012-07-25 Isis Pharmaceuticals Inc Modulation of transthyretin expression for the treatment of cns related disorders
CA2984026C (en) 2008-10-09 2020-02-11 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
KR101624869B1 (en) 2008-10-20 2016-05-30 알닐람 파마슈티칼스 인코포레이티드 Compositions and methods for inhibiting expression of transthyretin
US8969353B2 (en) 2008-11-07 2015-03-03 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
KR20220138415A (en) 2008-11-10 2022-10-12 알닐람 파마슈티칼스 인코포레이티드 Novel lipids and compositions for the delivery of therapeutics
US9493774B2 (en) 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
CA3036963A1 (en) 2009-01-29 2010-08-05 Arbutus Biopharma Corporation Lipid formulations comprising cationic lipid and a targeting lipid comprising n-acetyl galactosamine for delivery of nucleic acid
KR102229618B1 (en) 2009-05-05 2021-03-18 알닐람 파마슈티칼스 인코포레이티드 Lipid compositions
HRP20211619T1 (en) 2009-06-10 2022-02-04 Arbutus Biopharma Corporation Improved lipid formulation
KR20120050429A (en) 2009-06-15 2012-05-18 알닐람 파마슈티칼스 인코포레이티드 Lipid formulated dsrna targeting the pcsk9 gene
US9051567B2 (en) 2009-06-15 2015-06-09 Tekmira Pharmaceuticals Corporation Methods for increasing efficacy of lipid formulated siRNA
US9101643B2 (en) 2009-11-03 2015-08-11 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR)
EP3329924B1 (en) 2010-03-29 2021-05-05 Alnylam Pharmaceuticals, Inc. Dsrna therapy for transthyretin (ttr) related ocular amyloidosis
US20230340473A1 (en) 2010-03-29 2023-10-26 Alnylam Pharmaceuticals, Inc. Sirna therapy for transthyretin (ttr) related ocular amyloidosis
MX343559B (en) 2010-04-29 2016-11-10 Ionis Pharmaceuticals Inc Modulation of transthyretin expression.
AU2011302152B2 (en) 2010-09-15 2015-06-11 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
CN103370054A (en) 2010-11-09 2013-10-23 阿尔尼拉姆医药品有限公司 Lipid formulated compositions and methods for inhibiting expression of EG5 and VEGF genes
CA2839896A1 (en) 2011-06-21 2012-12-27 Alnylam Pharmaceuticals, Inc. Assays and methods for determining activity of a therapeutic agent in a subject
KR102263352B1 (en) 2011-11-18 2021-06-11 알닐람 파마슈티칼스 인코포레이티드 RNAi AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASES
EA201490993A1 (en) * 2011-11-18 2014-09-30 Элнилэм Фармасьютикалз, Инк. MODIFIED MEANS OF RNA
WO2013166041A1 (en) 2012-05-01 2013-11-07 The Trustees Of Columbia University In The City Of New York Transthyretin ligands capable of inhibiting retinol-dependent rbp4-ttr interaction for treatment of age-related macular
US9708607B2 (en) 2012-08-03 2017-07-18 Alnylam Pharmaceuticals, Inc. Modified RNAi agents
TW201610151A (en) * 2013-09-23 2016-03-16 阿尼拉製藥公司 Methods for treating or preventing transthyretin (TTR) associated diseases
EP3077511A4 (en) 2013-12-06 2017-07-05 Dicerna Pharmaceuticals Inc. Methods and compositions for the specific inhibition of transthyretin (ttr) by double-stranded rna
WO2015089368A2 (en) * 2013-12-12 2015-06-18 Alnylam Pharmaceuticals, Inc. Complement component irna compositions and methods of use thereof
KR102630289B1 (en) 2014-08-20 2024-01-31 알닐람 파마슈티칼스 인코포레이티드 Modified double-stranded rna agents
PT3185957T (en) 2014-08-29 2022-09-05 Alnylam Pharmaceuticals Inc Methods of treating transthyretin (ttr) mediated amyloidosis
EP4029859A1 (en) 2014-11-21 2022-07-20 Bsim Therapeutics, S.A. 2-oxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof
MX2018000981A (en) * 2015-07-31 2018-06-11 Alnylam Pharmaceuticals Inc TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES.
US20190350962A1 (en) 2016-12-16 2019-11-21 Alnylam Pharmaceuticals, Inc. METHODS FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES USING TRANSTHYRETIN (TTR) iRNA COMPOSITIONS
KR20200089656A (en) 2017-09-19 2020-07-27 알닐람 파마슈티칼스 인코포레이티드 Compositions and methods for treating transthyretin (TTR) mediated amyloidosis
EP3856907A1 (en) 2018-09-28 2021-08-04 Alnylam Pharmaceuticals, Inc. Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
WO2021041884A1 (en) 2019-08-30 2021-03-04 Alnylam Pharmaceuticals, Inc. Neurofilament light chain (nfl) as a biomarker for transthyretin amyloidosis polyneuropathy
WO2021092145A1 (en) 2019-11-06 2021-05-14 Alnylam Pharmaceuticals, Inc. Transthyretin (ttr) irna composition and methods of use thereof for treating or preventing ttr-associated ocular diseases
JP2023516748A (en) 2020-03-06 2023-04-20 アルナイラム ファーマシューティカルズ， インコーポレイテッド Compositions and methods for inhibiting expression of transthyretin (TTR)
WO2022235537A1 (en) 2021-05-03 2022-11-10 Alnylam Pharmaceuticals, Inc. Compositions and methods for treating transthyretin (ttr) mediated amyloidosis
WO2022260939A2 (en) 2021-06-08 2022-12-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for treating or preventing stargardt's disease and/or retinal binding protein 4 (rbp4)-associated disorders
EP4381067A1 (en) 2021-08-03 2024-06-12 Alnylam Pharmaceuticals, Inc. Transthyretin (ttr) irna compositions and methods of use thereof

Also Published As

Publication number Publication date
TWI727963B (en) 2021-05-21
US20170029817A1 (en) 2017-02-02
ZA201902447B (en) 2021-10-27
NL301216I2 (en) 2023-05-24
KR20240074895A (en) 2024-05-28
MY195720A (en) 2023-02-07
EP3329002A1 (en) 2018-06-06
US20230022185A1 (en) 2023-01-26
PL3329002T3 (en) 2021-04-19
CY1124545T1 (en) 2022-07-22
JP2021167313A (en) 2021-10-21
FIC20230006I1 (en) 2023-02-06
IL256614A (en) 2018-02-28
LT3329002T (en) 2021-01-11
TW202344688A (en) 2023-11-16
US10208307B2 (en) 2019-02-19
US10683501B2 (en) 2020-06-16
SG10201912341SA (en) 2020-02-27
CN116064515A (en) 2023-05-05
HUE051998T2 (en) 2021-04-28
MA43335B1 (en) 2021-01-29
CN108138182B (en) 2022-08-19
JP2018523655A (en) 2018-08-23
MA43335A (en) 2018-06-06
BR112018000542B1 (en) 2023-01-24
IL296476A (en) 2022-11-01
HUS2300007I1 (en) 2023-02-28
JP7417559B2 (en) 2024-01-18
PT3329002T (en) 2021-01-12
US20200377889A1 (en) 2020-12-03
HRP20202082T1 (en) 2021-02-19
US12049628B2 (en) 2024-07-30
NO2023007I1 (en) 2023-02-07
BR112018000542A2 (en) 2018-09-18
MX2018000981A (en) 2018-06-11
DK3329002T3 (en) 2021-01-11
CA2994285A1 (en) 2017-02-09
US11286486B2 (en) 2022-03-29
RS61297B1 (en) 2021-02-26
TW201718855A (en) 2017-06-01
KR102667020B1 (en) 2024-05-21
US20190345492A1 (en) 2019-11-14
EP3329002B1 (en) 2020-10-07
UA126276C2 (en) 2022-09-14
EA201890394A1 (en) 2018-08-31
IL256614B2 (en) 2023-02-01
FR23C1008I1 (en) 2023-03-24
LTPA2023505I1 (en) 2023-02-27
MX2023012080A (en) 2023-10-25
WO2017023660A1 (en) 2017-02-09
JP6896703B2 (en) 2021-06-30
TW202130810A (en) 2021-08-16
ES2842300T3 (en) 2021-07-13
CN108138182A (en) 2018-06-08
HK1256494A1 (en) 2019-09-27
IL296476B1 (en) 2024-06-01
HK1256683A1 (en) 2019-10-04
ZA201800571B (en) 2019-07-31
SI3329002T1 (en) 2021-02-26
IL313082A (en) 2024-07-01
KR20180028537A (en) 2018-03-16
CL2018000198A1 (en) 2018-07-20
IL256614B (en) 2022-10-01
JP2024028749A (en) 2024-03-05
TWI807302B (en) 2023-07-01
NL301216I1 (en) 2023-02-08

Similar Documents

Publication Publication Date Title
FR23C1008I2 (en) TRANSTHYRETIN (TTR) RNAI COMPOSITIONS AND METHODS OF USING THEM FOR THE TREATMENT OR PREVENTION OF TTR-ASSOCIATED DISEASES
MA45192A (en) ASSOCIATION TREATMENT
MA45481A (en) USE OF EXOSOMES FOR THE TREATMENT OF DISEASES
MA46098A (en) METHODS FOR PREVENTING OR TREATING ALLERGY BY GIVING AN IL-4 R ANTAGONIST
SG10201913552UA (en) Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions
MA42819A (en) METHODS FOR THE TREATMENT OF ARENAVIRIDAE AND CORONAVIRIDAE VIRAL INFECTIONS
MA44873A (en) COMPOSITION FOR THE TREATMENT OF MACULAR DEGENERATION RELATED TO EXSUDATIVE AGE
MA45798A (en) MASP-3 INHIBITION COMPOSITIONS AND METHODS FOR THE TREATMENT OF VARIOUS DISEASES AND CONDITIONS
MA47719A (en) ESKETAMINE FOR THE TREATMENT OF DEPRESSION
FR3014694B1 (en) METHYL-CYCLODEXTRIN-BASED COMPOSITIONS FOR THE TREATMENT AND / OR PREVENTION OF DISEASES BY INCREASING THE CHOLESTEROL-HDL RATE
MA44234A (en) METHODS FOR THE TREATMENT OR PREVENTION OF ATHEROSCLEROSIS BY ADMINISTRATION OF AN ANGPTL3 INHIBITOR
MA44875A (en) COMPOSITIONS FOR THE TREATMENT OF ACID BASIC DISORDERS
MA56412A (en) MESSENGER RNA THERAPY FOR THE TREATMENT OF JOINT DISEASES
MA42953A (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISORDERS
MA53568A (en) DRUGS FOR THE TREATMENT OF OPHTHALMIC DISEASES
FR3017298B1 (en) CONJUGATES AND PRO-DRUGS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES
MA53741A (en) METHODS OF TREATING MYELOPROLIFERATIVE DISORDERS
MA46641A (en) METHODS AND COMPOSITIONS FOR PREVENTING THE TRANSMISSION OF VECTOR-SPREAD DISEASES
MA39950A (en) 2-ACYLAMINOTHIAZOLE DERIVATIVE FOR THE TREATMENT OF URINARY TRACT AND BLADDER DISEASES
MA39927A (en) GLYT1 INHIBITORS FOR THE TREATMENT OF BLOOD DISORDERS
MA45973A (en) BTK INHIBITOR COMBINATIONS FOR THE TREATMENT OF MULTIPLE MYELOMA
MA41120A (en) COMPOSITIONS INCLUDING 15-HEPE AND METHODS OF TREATING OR PREVENTING FIBROSIS USING THEM
FR3022139B1 (en) NEW COMPOSITIONS FOR THE TREATMENT OF SKIN FLAVORS AND ROSACEA
MA47595A (en) TREATMENT METHODS FOR NEURODEGENERATIVE DISORDERS
MA42985A (en) TREATMENT OF BILIARY ACID-RELATED DISORDERS